Nanovial tools to map how single cells talk to each other at scale
Official title: Nanovial Kits for Large-Scale Cell-Cell Interaction Sequencing
Funded at Partillion Bioscience Corporation · NIH-11410488 · Data updated 2026-11-12
New technology to study how individual cells communicate and affect each other, using easy-to-use nanovial kits with common single-cell sequencing methods.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Partillion Bioscience Corporation NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $979,071 |
| NIH project number | 1R44GM165220-01 |
| Project ID | NIH-11410488 on NIH RePORTER |
Who could benefit from this research
✓Could help
Researchers and clinicians seeking to understand cell interactions in disease contexts could use these tools to advance therapy development.
✕Less likely to help
Direct patient benefit may be limited to future therapies; this project does not enroll patients.
What this research studies
This project adapts nanovial technology to work with widely used sequencing kits so researchers can study large numbers of single-cell interactions cost-effectively. It aims to create standardized workflows, including formats that limit unintended interactions and reliable data capture, so results are easy to interpret. By testing two big use cases, the work strives to generate large, meaningful datasets that could accelerate therapeutic discovery and help train AI models that understand cell communication.
Why it matters
Potential benefit: If successful, patients could benefit from faster development of therapies informed by a clearer map of how cells interact.
How similar studies have gone: Previous uses of nanovials for single-cell assays show promise, and expanding compatibility with sequencing kits aims to broaden impact.
Where this research is happening
-
Partillion Bioscience Corporation
Los Angeles, United States Active
Researchers
- Principal investigator: De Rutte, Joseph — Partillion Bioscience Corporation
- Study coordinator: De Rutte, Joseph
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.